Evaluation of disease progression in patients with ATTR amyloidosis with cardiomyopathy following treatment with patisiran: Post-hoc analysis of the APOLLO-B study
Thibaud Damy(Amyloidosis Foundation), Mazen Hanna(Cleveland Clinic), Brian Drachman(Penn Presbyterian Medical Center), Laura Obici(University of Pavia), K. Capocelli(Alnylam Pharmaceuticals (United States)), Shaun Bender(Alnylam Pharmaceuticals (United States)), Michael Polydefkis(Université Paris-Sud), V. Pedro-Schwartzmann(Hospital São Paulo), Cláudio Tinoco Mesquita(Universidade Federal Fluminense), Zubair Shah(University Medical Center), P. Jay(Alnylam Pharmaceuticals (United States))
Cited by 0
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2021|1.1k